News Center



News Center

In 2023

Viwit Pharmaceuticals' Vildagliptin Tablets Receive Official Approval by China NMPA

Viwit Pharmaceuticals' Vildagliptin Tablets Receive Official Approval by China NMPA

Viwit Pharmaceuticals is pleased to announce the acquisition of the Drug Registration Certificate (Certificate No: 2023S01974) from the National Medical Products Administration (NMPA) for a proprietary finished dosage form, Vildagliptin tablet. This signifies the official approval of this product in the Chinese market.

22

2023

/

12

Viwit Pharmaceuticals' Lidocaine Injection Receives Official Approval by China NMPA

Viwit Pharmaceuticals' Lidocaine Injection Receives Official Approval by China NMPA

On December 18, 2023, Viwit Pharmaceuticals received the "Drug Supplementary Application Approval Notice" (Notice No: 2023B06224) issued by the China National Medical Products Administration for a proprietary finished dosage form, Lidocaine Hydrochloride for Injection (5ml: 0.1g).

19

2023

/

12

Viwit Pharmaceuticals' Vildagliptin API Receives Official Approval by China NMPA

Viwit Pharmaceuticals' Vildagliptin API Receives Official Approval by China NMPA

On November 30, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by National Medical Products Administration (NMPA) for its independently developed active pharmaceutical ingredient (API), Vildagliptin. The registration number is Y20210000619, and the notice number is 2023YS00803.

07

2023

/

12

Viwit Pharmaceuticals' Aprepitant API Receives Official Approval by China NMPA

Viwit Pharmaceuticals' Aprepitant API Receives Official Approval by China NMPA

On October 26, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for the independently developed active pharmaceutical ingredient (API) Aprepitant. The registration number is Y20210000473, and the notice number is 2023YS00727.

31

2023

/

10

Viwit Pharmaceuticals obtained the Drug Production License C

Viwit Pharmaceuticals obtained the Drug Production License C

Congratulations to Viwit Pharmaceuticals that Viwit obtained the Drug Production License C for solid preparations and injections on July 28th, 2023. Meaning, that Viwit’s production lines for solid preparations and injections own the qualification on contracted manufacturing.

30

2023

/

10

Viwit Pharmaceuticals’BFS Technology

Viwit Pharmaceuticals’BFS Technology

Viwit’s sterile blow-fill-seal (BFS) eye drops manufacturing facility is established in 2021. The BFS production line fulfills the need for an advanced aseptic manufacturing process using the state of the art Rommelag 434 BFS system. Pharmaceutical grade low-density polyethylene (PE) is used to ensure product quality and prevent leachable and leakage. A strip of 15 doses attached to each other can be created and filled within a few seconds. Every single BFS ampule is detected for leakage to ensure the integrity of the dose.

18

2023

/

10

Meeting Viwit Pharmaceuticals at CPHI Barcelona

Meeting Viwit Pharmaceuticals at CPHI Barcelona

Viwit Pharmaceuticals will be participating in CPHI Barcelona 2023 in Oct. 24th~26th, 2023 at Fira Barcelona Gran Via, Spain. Welcome to visit our booth 7D30 or contact us to learn more about our full portfolio of products, services, and solutions. We look forward to seeing you soon!

18

2023

/

09

SST Corporation and Viwit Pharmaceuticals Establish Strategic Collaboration

SST Corporation and Viwit Pharmaceuticals Establish Strategic Collaboration

Having become an officially qualified API/CMC supplier to SST Corporation, Viwit and SST have established a strategic collaboration aiming to promote small molecule pharmaceutical contract development and manufacturing organization (CDMO) services in North America.

11

2023

/

08

< 12 >

Search

Confirm
%{tishi_zhanwei}%